Factors predictive of virological failure on atazanavir in 310 HIV-infected patients

AIDS

Volumn 24, Issue 10, 2010, Pages 1593-1595

  Lescure, François Xavier ^a   Poirier, Jean Marie ^b   Meynard, Jean Luc ^c   Guiard Schmid, Jean Baptiste ^a   Zouai, Ouahiba ^b   Bonnard, Philippe ^a   Slama, Laurence ^a   Amiel, Corinne ^b   Girard, Pierre Marie ^c   Pialoux, Gilles ^a  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR;

ADULT; AGED; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; ROC CURVE; VIRAL LOAD; YOUNG ADULT;

EID: 77953916728     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833a2403     Document Type: Article

References (13)

1. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. 96-week comparison of once-daily ATV/RTV and twice-daily lopinavir/RTV in patients with multiple virologic failures. AIDS 2006; 20:711-718.
2. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. ATV plus RTV or saquinavir, and lopinavir/RTV in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.
3. Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, et al. Comparison of ATV with lopinavir/RTV in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005; 21:1683-1692.
4. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, et al. Comparison of once-daily ATV with efavir-enz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-1019.
5. Noor MA, Flint OP, Maa JF, Parker RA. Effects of ATV/RTV and lopinavir/RTV on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
6. GonzalezdeRequenaD,BonoraS,CantaF,MarroneR,D'Avolio A, Sciandra M, et al. ATV Ctrough is associated with efficacy and safety: definition of therapeutic range. 12th CROI 2005.
7. Bertz R, Wang Y, Mahnke L, Persson A, Chung E, Mathew M, et al. Assessment of pharmacokinetics/pharmacodynamics relationships through 48 weeks from a study in HIVR, ARV-näive subjects receiving antiretroviral regimens containing ATV 400mg or ATV/RTV 300/100mg once daily. 14th CROI 2007.
8. Santoro MM, Bertoli A, Lorenzini P, Lazzarin A, Esposito R, Carosi G, et al., CARe Study Group. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS Patient Care STDS 2008; 22:7-16.
9. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Gonzalez-Pardo G, Jimenez-Nacher I, Gonzalez-Lahoz J, et al. Genetic factors influencing ATV plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21:41-46.
10. Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med 2010; 11:326-333.
11. Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, et al. Efficacy and safety of ATV-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484-1492.
12. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritona-vir, each in combination with tenofovir and emtricitabine in ARV-näive HIV-1-infected subjects: the CASTLE study. Lancet 2008; 372:646-655.
13. Santoro MM, Bertoli A, Lorenzini P, Lazzarin A, Esposito R, Carosi G, et al. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe study. AIDS Patient Care STDS 2008; 22:7-16.